Ironwood Pharmaceuticals Reports Third Quarter 2019 Results; Raises Full Year 2019 Guidance
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS® (linaclotide) Collaboration in China
Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment
Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering
Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes
Ironwood Pharmaceuticals to Highlight IW-3718 and Linaclotide Data at Digestive Disease Week® 2019